Food and Drug Administration (FDA) for the IMPACT Dx(TM) Factor V Leiden
and Factor II Genotyping Test and the IMPACT Dx(TM) System.
Women were not excluded if they were heterozygous for a factor V Leiden
Summary: One in five patients diagnosed with blood clots (thrombosis) at Mafraq Hospital carries a genetic protein mutation known as Factor V Leiden
Factor V Leiden
and prothrombin G20210A mutation allele frequencies in Europeans are been reported to be 1.
Thrombotic screen testing revealed a heterozygous factor V Leiden
mutation and a bleeding screen type I von Willebrand disease (vWD).
Mammo L, Daalan A, Bahabri S et al: Association of factor V leiden
with Behcet's disease.
For sample size estimation, we assumed that the frequency of any one variant allele for either factor V Leiden
or prothrombin in patients with idiopathic PE (n = 49) would be at least 20% higher than the frequency in each of the control groups; with a = 0.
4-7) More than 95% of cases are due to a point mutation, known as the factor V Leiden
mutation, at 1 of the 3 arginine cleavage sites in the factor V gene.
The defect, affecting a gene called Factor V Leiden
, was associated with a poor rate of live births in a study of pregnancy outcomes.
This was named Factor V Leiden
(8), which was found in as much as 10 percent of the population of some European countries, and in 5 percent of Caucasians in the United States.
ABSTRACT: Factor V Leiden
is a well-recognized etiology of venous thrombosis, but reports of stroke in patients with this mutation are few.
Since it has been suggested that thrombosis is a multicausal disease due to multiple risk factors, the current findings complement the two common genetic variants, Factor V Leiden
and prothrombin G20210A, that have been consistently found to be associated with DVT.